416 related articles for article (PubMed ID: 30355943)
1. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
[TBL] [Abstract][Full Text] [Related]
2. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
[TBL] [Abstract][Full Text] [Related]
3. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
Tapia O; Riquelme I; Leal P; Sandoval A; Aedo S; Weber H; Letelier P; Bellolio E; Villaseca M; Garcia P; Roa JC
Virchows Arch; 2014 Jul; 465(1):25-33. PubMed ID: 24844205
[TBL] [Abstract][Full Text] [Related]
4. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
5. CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway.
Zang M; Zhang B; Zhang Y; Li J; Su L; Zhu Z; Gu Q; Liu B; Yan M
PLoS One; 2014; 9(11):e112908. PubMed ID: 25398131
[TBL] [Abstract][Full Text] [Related]
6. Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway.
Li J; Ye D; Shen P; Liu X; Zhou P; Zhu G; Xu Y; Fu Y; Li X; Sun J; Xu J; Zhang Q
J Exp Clin Cancer Res; 2020 Oct; 39(1):212. PubMed ID: 33032635
[TBL] [Abstract][Full Text] [Related]
7. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
8. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA hsa_circ_0010882 promotes the progression of gastric cancer via regulation of the PI3K/Akt/mTOR signaling pathway.
Peng YK; Pu K; Su HX; Zhang J; Zheng Y; Ji R; Guo QH; Wang YP; Guan QL; Zhou YN
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1142-1151. PubMed ID: 32096170
[TBL] [Abstract][Full Text] [Related]
10. Upregulated hsa_circRNA_100269 inhibits the growth and metastasis of gastric cancer through inactivating PI3K/Akt axis.
Wang Z; Liu C
PLoS One; 2021; 16(4):e0250603. PubMed ID: 33901239
[TBL] [Abstract][Full Text] [Related]
11. HOXB13 promotes gastric cancer cell migration and invasion via IGF-1R upregulation and subsequent activation of PI3K/AKT/mTOR signaling pathway.
Guo C; Chu H; Gong Z; Zhang B; Li C; Chen J; Huang L
Life Sci; 2021 Aug; 278():119522. PubMed ID: 33894267
[TBL] [Abstract][Full Text] [Related]
12.
Qian Y; Yan Y; Lu H; Zhou T; Lv M; Fang C; Hou J; Li W; Chen X; Sun H; Li Y; Wang Z; Zhao N; Gu Y; Ding Y; Liu Y
Anticancer Agents Med Chem; 2019; 19(14):1754-1761. PubMed ID: 31364518
[TBL] [Abstract][Full Text] [Related]
13. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway.
Zhang X; Wang S; Wang H; Cao J; Huang X; Chen Z; Xu P; Sun G; Xu J; Lv J; Xu Z
Mol Cancer; 2019 Feb; 18(1):20. PubMed ID: 30717751
[TBL] [Abstract][Full Text] [Related]
15. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway.
Huang YK; Kang WM; Ma ZQ; Liu YQ; Zhou L; Yu JC
Carcinogenesis; 2019 Apr; 40(2):370-379. PubMed ID: 30371738
[TBL] [Abstract][Full Text] [Related]
16. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
Sun C; Tao Y; Gao Y; Xia Y; Liu Y; Wang G; Gu Y
Biomed Pharmacother; 2018 Feb; 98():416-423. PubMed ID: 29278851
[TBL] [Abstract][Full Text] [Related]
17. miR-5590-3p inhibited tumor growth in gastric cancer by targeting DDX5/AKT/m-TOR pathway.
Wu N; Han Y; Liu H; Jiang M; Chu Y; Cao J; Lin J; Liu Y; Xu B; Xie X
Biochem Biophys Res Commun; 2018 Sep; 503(3):1491-1497. PubMed ID: 30029874
[TBL] [Abstract][Full Text] [Related]
18. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.
Du W; Wang S; Zhou Q; Li X; Chu J; Chang Z; Tao Q; Ng EK; Fang J; Sung JJ; Yu J
Oncogene; 2013 Jul; 32(28):3319-28. PubMed ID: 22907434
[TBL] [Abstract][Full Text] [Related]
19. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway.
Riquelme I; Tapia O; Leal P; Sandoval A; Varga MG; Letelier P; Buchegger K; Bizama C; Espinoza JA; Peek RM; Araya JC; Roa JC
Cell Oncol (Dordr); 2016 Feb; 39(1):23-33. PubMed ID: 26458815
[TBL] [Abstract][Full Text] [Related]
20. Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway.
Ni T; Wang H; Li D; Tao L; Lv M; Jin F; Wang W; Feng J; Qian Y; Sunagawa M; Liu Y
Biomed Pharmacother; 2019 Oct; 118():109241. PubMed ID: 31351435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
